1. Bypass Versus Drug-Eluting Stents at Three Years in SYNTAX Patients With Diabetes Mellitus or Metabolic Syndrome 
Michael J. Mack, MD, Adrian P. Banning, MD, Patrick W. Serruys, MD, PhD, Marie-Claude Morice, MD, Yves Taeymans, MD, Guido Van Nooten, MD, PhD, Gianfederico Possati, MD, Filippo Crea, MD, Kristin L. Hood, PhD, Katrin Leadley, MD, Keith D. Dawkins, MD, A. Pieter Kappetein, MD, PhD 
The Annals of Thoracic Surgery 
Volume 92, Issue 6, Pages (December 2011)
DOI: /j.athoracsur
Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
Patients included in the analysis. (A) Patients included in the diabetes mellitus analysis. (B) Overlap between diabetes and metabolic syndrome. (CABG = coronary artery bypass graft surgery; PES = paclitaxel-eluting stent.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
Three-year outcomes for diabetic patients and nondiabetic patients according to anatomic lesion complexity, as measured by the SYNTAX score. (A, D) Major adverse cardiac and cerebrovascular events (MACCE), (B, E) composite death/cerebrovascular accident (CVA)/myocardial infarction (MI), and (C, F) revascularization in (A–C) patients with medically treated diabetes and (D–F) without medically treated diabetes. Rates are separated by SYNTAX Scores, indicating low (≤22), medium (23 to 32), and high (≥33) anatomic lesion complexity. (CABG = coronary artery bypass graft surgery [open bars]; PES = paclitaxel-eluting stent [solid bars].)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions